Hossein MOHSENZADEH, Plaintiff-Appellant v. Michelle K. LEE, Director, U.S. Patent and Trademark Office, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office, Defendant-Appellee.
No. 2014-1499.
United States Court of Appeals, Federal Circuit.
June 25, 2015.
790 F.3d 1377
Dana Kaersvang, Appellate Staff, Civil Division, United States Department of Justice, Washington, DC, argued for defendant-appellee. Also represented by Mark R. Freeman; Antonia Konkoly, Office of the United States Attorney for the Eastern District of Virginia, Alexandria, VA; Brian Thomas Racilla, Meredith Hope Schoenfeld, Nathan K. Kelley, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, VA.
Before MOORE, SCHALL, and REYNA, Circuit Judges.
REYNA, Circuit Judge.
Hossein Mohsenzadeh appeals the district court‘s entry of summary judgment in favor of the government on the issue of whether the United States Patent and Trademark Office (“PTO“) properly calculated patent term adjustments for two patents that issued from divisional applications. Because we find that the district court did not err in affirming the PTO‘s denial of Mohsenzadeh‘s requests for patent term adjustments, we affirm.
I. BACKGROUND
A. PATENT TERM ADJUSTMENTS
The patent term adjustment statute,
This appeal concerns only A Delay. The relevant statutory provision,
[I]f the issue of an original patent is delayed due to the failure of the Patent and Trademark Office to—
(i) provide at least one of the notifications under section 132 or a notice of allowance under section 151 not later than 14 months after—
(I) the date on which an application was filed under section 111(a); or
(II) the date of commencement of the national stage under section 371 in an international application
. . .
the term of the patent shall be extended 1 day for each day [of delay]
The impact of a late-mailed restriction requirement forms the basis of this appeal. When an application is filed with claims drawn to multiple inventions, the PTO may issue a restriction requirement, which re-
After a patent is granted, the Director of the PTO must issue a patent term adjustment that adds one day of patent term for each day of A or B Delay attributable to the PTO.
The period of adjustment of the term of a patent . . . shall be reduced by a period equal to the period of time during which the applicant failed to engage in reasonable efforts to conclude prosecution of the application.
B. MOHSENZADEH‘S PATENT APPLICATIONS
Mohsenzadeh filed Application No. 09/899,905 (“‘905 application“) on July 6, 2001. The ‘905 application included 58 claims. Though the 14-month notification period of
The claims Mohsenzadeh elected to prosecute issued on June 22, 2010 as U.S. Patent No. 7,742,984 (“‘984 patent“). When the patent issued, the PTO granted a patent term adjustment of 2,104 days for the ‘984 patent. That figure includes 1,476 days of A Delay attributable to the delay occurring between September 6, 2002 and September 21, 2006, i.e., the time between when notice was due and when the PTO actually provided notice of the restriction requirement.
Mohsenzadeh filed two divisional applications from the ‘905 application on January 8, 2010. Each divisional application corresponded to a group of claims identified as a separate invention in the original restriction requirement. Both applications issued as patents. The first, U.S. Patent No. 8,352,362 (“‘362 patent“), issued on January 8, 2013, and the second, U.S. Patent No. 8,401,963 (“‘963 patent“), issued on March 19, 2013. Both patents claim priority to the ‘984 patent. The PTO granted 0 days of patent term adjustment for both the ‘362 and ‘963 patents.
C. MOHSENZADEH‘S CHALLENGES TO TERM ADJUSTMENTS
Pursuant to agency regulations, Mohsenzadeh requested reconsideration of the patent term adjustments for both the ‘362 and ‘963 patents. He argued that each patent was entitled to the 1,476 days that the PTO delayed in issuing the restriction requirement for the ‘984 patent. The PTO denied both requests, reasoning that
Mohsenzadeh filed an action challenging the denials of his reconsideration requests under
Mohsenzadeh appeals from the grant of summary judgment to the government. We have jurisdiction under
II. DISCUSSION
Both Mohsenzadeh and the government focus their arguments on the text of
if the issue of an original patent is delayed due to the failure of the Patent and Trademark Office to—
(i) provide at least one of the notifications under section 132 or a notice of allowance under section 151 not later than 14 months after—
(I) the date on which an application was filed under section 111(a); or
(II) the date of commencement of the national stage under section 371 in an international application;
. . .
the term of the patent shall be extended 1 day for each day [of delay]
The government responds by arguing that
(14) Further prosecution via a continuing application, in which case the period of adjustment . . . shall not include any period that is prior to the actual filing date of the application that resulted in the patent.
A. STANDARD OF REVIEW
We review a district court‘s grant of summary judgment under the law of the regional circuit, in this case the Fourth Circuit. Fox Grp., Inc. v. Cree, Inc., 700 F.3d 1300, 1303 (Fed. Cir. 2012). The Fourth Circuit reviews the grant of summary judgment de novo, “viewing all facts and reasonable inferences therefrom in the light most favorable to the nonmoving party.” Fraternal Order of Police Metro Transit Police Labor Comm., Inc. v. Wash. Metro. Area Transit Auth., 780 F.3d 238, 241 (4th Cir. 2015). Similarly, we review questions of pure statutory interpretation without deference to the district court. AD Global Fund, LLC v. United States, 481 F.3d 1351, 1353 (Fed. Cir. 2007).
B. THE STATUTE‘S PLAIN LANGUAGE RESOLVES THE DISPUTE
The language of the provision of the patent term adjustment statute at issue,
As the government argues, Congress’ insertion of the provision governing international applications in
CONCLUSION
Because the plain language of
AFFIRMED
Costs
No costs.
